Story

Abcellera Biologics Shares Decline on $200 Million Stock Offering News

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Abcellera Biologics Shares Decline on $200 Million Stock Offering News
Text size
Background

Shares of Abcellera Biologics (ABCL) fell 4.1% in after-hours trading after the company announced its intent to launch a proposed underwritten public offering. The move to raise capital comes just one day after the stock surged on promising clinical trial results.

The Offering Details

Abcellera plans to offer $200 million in common shares and pre-funded warrants, with the company receiving all proceeds from the sale. According to the announcement, the capital is intended to fund research, development, and clinical advancement for its internal pipeline, particularly its lead program, ABCL635.

The funds will also be used for working capital and general corporate purposes. The offering is being managed by a syndicate of banks, with Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets acting as joint book-running managers.

Market Reaction and Context

The after-hours stock decline is a direct reaction to the dilutive nature of the offering. By issuing new shares, a company increases the total number of shares outstanding, which can reduce the ownership percentage and earnings per share for existing investors.

Sample IUX Markets – In-articleAd

The timing of the capital raise is notable, as it follows a roughly 35% surge in Abcellera's stock price during the prior trading session. The company is capitalizing on a recent 52-week high of $10.29 to raise funds at a more favorable valuation.

Positive Clinical Catalyst

The preceding rally was fueled by positive data from a Phase 2 trial of ABCL635, a potential first-in-class antibody for treating hot flashes in menopausal women. The company reported the drug delivered an 83% mean reduction in hot flash frequency at week four.

Following the news, Truist Securities raised its price target on the stock to $30 from a previous $12, maintaining a Buy rating. The firm cited increased peak risk-adjusted sales estimates for ABCL635, projecting potential sales of $1.1 billion.

Read next

More on Stocks
Back to latest news

LATEST